Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study
Open Access
- 1 January 2005
- journal article
- clinical trial
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 71 (1), 61-65
- https://doi.org/10.1007/s11060-004-9176-0
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Phase II study of temozolomide in heavily pretreated cancer patients with brain metastasesAnnals of Oncology, 2001
- A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain MetastasesJournal of Neuro-Oncology, 2001
- Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells.2000
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaJournal of Clinical Oncology, 2000
- Brain metastases in breast cancer: prognostic factors and managementEuropean Journal Of Cancer, 1999
- Response of Brain Metastases from Lung Cancer to Systemic Chemotherapy with Carboplatin and EtoposideOncology, 1996
- Cisplatin Increases Sensitivity of Human Leukemic Blasts to Triazene CompoundsJournal of Chemotherapy, 1995
- Inactivation of O6-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatinCarcinogenesis: Integrative Cancer Research, 1989
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958